Cite
Mirandola L, Pedretti E, Figueroa JA, et al. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget. 2017;8(43):74378-74390doi: 10.18632/oncotarget.20102.
Mirandola, L., Pedretti, E., Figueroa, J. A., Chiaramonte, R., Colombo, M., Chapman, C., Grizzi, F., Patrinicola, F., Kast, W. M., Nguyen, D. D., Rahman, R. L., Daver, N., Ruvolo, P., Post, S. M., Bresalier, R. S., & Chiriva-Internati, M. (2017). Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget, 8(43), 74378-74390. https://doi.org/10.18632/oncotarget.20102
Mirandola, Leonardo, et al. "Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy." Oncotarget vol. 8,43 (2017): 74378-74390. doi: https://doi.org/10.18632/oncotarget.20102
Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget. 2017 Aug 10;8(43):74378-74390. doi: 10.18632/oncotarget.20102. eCollection 2017 Sep 26. PMID: 29088794; PMCID: PMC5650349.
Copy
Download .nbib